Determining the Subjective and Physiological Effects of BZP Combined with TFMPP in Human Males

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2010 Nov 10

PMID 21060995

Citations 7

Authors

Joanne C Lin

Reem K Jan

Heeseung Lee

Maree-Ann Jensen

Rob R Kydd

Bruce R Russell

Affiliations

Soon will be listed here.

Abstract

Rationale: ‘Party Pills’ containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been used in a recreational context since the 1990s and, prior to April 2008, were legally available in New Zealand. Taken together, they have been reported to produce a ‘high’ similar to that produced by 3,4-methylenedioxymethamphetamine (MDMA).

Objectives: There has been little research on the subjective effects of piperazines in humans. The purpose of this study is to further investigate the subjective and physiological responses following an oral dose of BZP combined with TFMPP in males.

Methods: In a randomised, double-blind, placebo-controlled study the subjective and physiological effects of BZP/TFMPP were investigated in 36 healthy, non-smoking males (mean age 22 ± 4 years). Participants were tested before and approximately 120 min after administration of a single dose of placebo (n = 16) or 100/30 mg BZP/TFMPP (n = 20). Participants were required to comment on the subjective effects using three rating scales—the Addiction Research Centre Inventory (ARCI), the Visual Analogue Scale (VAS) and the Profile of Mood States (POMS). Participants' blood pressure, heart rate and body temperature were also measured.

Results: Statistical analysis using repeated-measures analysis of variance (ANOVA) and planned comparisons revealed that BZP/TFMPP significantly increases blood pressure and heart rate (p < 0.05). Likewise, the subjective rating scales revealed that BZP/TFMPP has significant dexamphetamine-like effects, increases dysphoria and feelings of self-confidence (p < 0.05).

Conclusion: These physiological and subjective data reflect clear similarities between the effects of BZP/TFMPP and commonly known stimulants such as dexamphetamine and MDMA.

Citing Articles

Designer drugs: mechanism of action and adverse effects.

Luethi D, Liechti M Arch Toxicol. 2020; 94(4):1085-1133.

PMID: 32249347 PMC: 7225206. DOI: 10.1007/s00204-020-02693-7.

Impure but not inactive: Behavioral pharmacology of dibenzylpiperazine, a common by-product of benzylpiperazine synthesis.

Dolan S, Shetty R, Forster M, Gatch M J Psychopharmacol. 2018; 32(7):802-810.

PMID: 29909719 PMC: 7504971. DOI: 10.1177/0269881118780613.

Monoamine Transporter and Receptor Interaction Profiles in Vitro Predict Reported Human Doses of Novel Psychoactive Stimulants and Psychedelics.

Luethi D, Liechti M Int J Neuropsychopharmacol. 2018; 21(10):926-931.

PMID: 29850881 PMC: 6165951. DOI: 10.1093/ijnp/pyy047.

Investigation of the effects of 'piperazine-containing party pills' and dexamphetamine on interhemispheric communication using electroencephalography.

Lee H, Wang G, Curley L, Kydd R, Kirk I, Russell B Psychopharmacology (Berl). 2016; 233(15-16):2869-77.

PMID: 27289365 DOI: 10.1007/s00213-016-4335-5.

Acute effects of the designer drugs benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) using functional magnetic resonance imaging (fMRI) and the Stroop task--a pilot study.

Curley L, Kydd R, Robertson M, Pillai A, McNair N, Lee H Psychopharmacology (Berl). 2015; 232(16):2969-80.

PMID: 25893641 DOI: 10.1007/s00213-015-3933-y.

References

Meririnne E, Kajos M, Kankaanpaa A, Seppala T . Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol. 2006; 98(4):346-50. DOI: 10.1111/j.1742-7843.2006.pto_243.x. View

Magyar K, Fekete M, Tekes K, Torok T . The action of trelibet, a new antidepressive agent on [3H]noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol. 1986; 130(3):219-27. DOI: 10.1016/0014-2999(86)90271-2. View

Antia U, Tingle M, Russell B . Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci. 2010; 55(5):1311-8. DOI: 10.1111/j.1556-4029.2010.01457.x. View

Appel J, Callahan P . Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. Eur J Pharmacol. 1989; 159(1):41-6. DOI: 10.1016/0014-2999(89)90041-1. View

McCall R, Patel B, HARRIS L . Effects of serotonin1 and serotonin2 receptor agonists and antagonists on blood pressure, heart rate and sympathetic nerve activity. J Pharmacol Exp Ther. 1987; 242(3):1152-9. View

Martin W, SLOAN J, SAPIRA J, Jasinski D . Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther. 1971; 12(2):245-58. DOI: 10.1002/cpt1971122part1245. View

Foltin R, FISCHMAN M . Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend. 1991; 28(1):3-48. DOI: 10.1016/0376-8716(91)90052-z. View

Miranda F, Orozco G, Velazquez-Martinez D . Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist. Behav Pharmacol. 2002; 13(4):303-11. DOI: 10.1097/00008877-200207000-00007. View

Saudou F, Amara D, Dierich A, Lemeur M, Ramboz S, Segu L . Enhanced aggressive behavior in mice lacking 5-HT1B receptor. Science. 1994; 265(5180):1875-8. DOI: 10.1126/science.8091214. View

10.

Antia U, Tingle M, Russell B . Metabolic interactions with piperazine-based 'party pill' drugs. J Pharm Pharmacol. 2009; 61(7):877-82. DOI: 10.1211/jpp/61.07.0006. View

11.

Thompson I, Williams G, Caldwell B, Aldington S, Dickson S, Lucas N . Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol. 2009; 24(9):1299-308. DOI: 10.1177/0269881109102608. View

12.

Nissbrandt H, Waters N, Hjorth S . The influence of serotoninergic drugs on dopaminergic neurotransmission in rat substantia nigra, striatum and limbic forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol. 1992; 346(1):12-9. DOI: 10.1007/BF00167564. View

13.

Auerbach S, Rutter J, Juliano P . Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis. Neuropharmacology. 1991; 30(4):307-11. DOI: 10.1016/0028-3908(91)90054-f. View

14.

Campbell H, Cline W, Evans M, Lloyd J, Peck A . Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol. 1973; 6(3):170-6. DOI: 10.1007/BF00558281. View

15.

Johnstone A, Lea R, Brennan K, Schenk S, Kennedy M, Fitzmaurice P . Benzylpiperazine: a drug of abuse?. J Psychopharmacol. 2007; 21(8):888-94. DOI: 10.1177/0269881107077260. View

16.

Fantegrossi W, Winger G, Woods J, Woolverton W, Coop A . Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend. 2005; 77(2):161-8. DOI: 10.1016/j.drugalcdep.2004.07.014. View

16.

White R, STANDEN O . Piperazine in the treatment of threadworms in children; report on a clinical trial. Br Med J. 1953; 2(4839):755-7. PMC: 2029560. DOI: 10.1136/bmj.2.4839.755. View

17.

Volkow N, Wang G, Ma Y, Fowler J, Wong C, Jayne M . Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage. 2006; 32(4):1782-92. DOI: 10.1016/j.neuroimage.2006.04.192. View

18.

Kalant H . The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ. 2001; 165(7):917-28. PMC: 81503. View

19.

Chait L, Johanson C . Discriminative stimulus effects of caffeine and benzphetamine in amphetamine-trained volunteers. Psychopharmacology (Berl). 1988; 96(3):302-8. DOI: 10.1007/BF00216054. View